TABLE 82Utility values for CML

Disease stageDrugGordois et al. (2003);244 Warren et al. (2004)233Reed et al. (2004);225 Reed et al. (2008)235Dalziel et al. (2005)226Kattan et al. (1996)234Liberato et al. (1997)245BMS (2009)184
MethodEQ-5DEQ-5DEQ-5DNot statedNot statedEQ-5D
Elicited fromSix cliniciansPatients in IRIS RCTPatients in IRIS RCTClinicians10 clinicians100 lay people
CP (CyR and no CyR)Imatinib0.900.854 (SE 0.004)0.854 (SD 0.19)0.85 responding to treatment, 0.68 not responding

Plus treatment-related AE disutility
Hydroxycarbamide0.900.90 (SD = 0.2)
IFN + cytarabine0.710 (SE 0.008)0.710 (SD 0.27)0.900.875
AP (no CyR)Imatinib0.580.595 (SE 0.077)0.729 (SD 0.204)0.50 plus treatment-related AE disutility
IFN + cytarabine0.595 (SE 0.077)0.729 (SD 0.204)0.50
BC (no CyR)Imatinib0.380.595 (SE 0.077)0.524 (SD 0.424)0.31 plus treatment-related AE disutility
IFN + cytarabine0.595 (SE 0.077)0.524 (SD 0.424)0.500.500

From: 5, Cost-effectiveness: chronic myeloid leukaemia in chronic phase

Cover of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid Leukaemia: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.22.
Rogers G, Hoyle M, Thompson Coon J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.